Skip to main content
Equibles
RVPH logo

RVPH · Reviva Pharmaceuticals Holdings, Inc. · Metrics

Track RVPH — free

Use RVPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RVPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.39 +0.04 (+10.76%) At close · May 14
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued. ... These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”
View the 10-Q filed Aug 12, 2026
Market Cap
$6.33M
Shares
13.11M
Volume · May 14 742.02K Avg daily vol (48 sessions) 985.8K

RVPH metrics

38 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.39
Market cap
$6.33M

Price action

23 metrics
Price change (1W)
-54.8%
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
20.3
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
985,801
Relative volume
0.8
Average dollar volume
$766,786

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
13.11M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.4
reciprocal yield 240.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-205.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$13.48M
Net income (TTM)
−$13.02M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.47

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+10.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-85.6%
Return on assets
-61.6%
Debt / equity
0.0
Current ratio
3.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.6
Interest coverage
-2,050.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$19.75M
Latest balance sheet
Cash & equivalents
$19.89M
Total assets
$21.14M
Total debt
$144,093

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$17.30M
Capital expenditures (TTM)
—
R&D (TTM)
$6.70M
SG&A (TTM)
—
Stock compensation (TTM)
$1.71M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
5
13F filer change QoQ
-33
Institutional ownership
0.1%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
-100.0%
Holder tenure
4.9
Price vs estimated holder cost
-99.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1742927 CUSIP 76152G209 13F (30d) 13 filings 3 filers Visit website Investor relations